No effect of risedronate on articular cartilage damage in the Dunkin Hartley guinea pig model of osteoarthritis

Scandinavian Journal of Rheumatology

Volumn 42, Issue 5, 2013, Pages 408-416

  Thomsen, J S ^a   Straarup, T S ^a   Danielsen, C C ^a   Oxlund, H ^a   Bruel A ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 2; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; BONE GROWTH; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIPHYSIS; HUMAN; MALE; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUBCHONDRAL BONE PLATE; TIBIA SHAFT;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; CARTILAGE, ARTICULAR; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; ELASTICITY; EPIPHYSES; ETIDRONIC ACID; GROWTH PLATE; GUINEA PIGS; MALE; OSTEOARTHRITIS; OSTEOCLASTS; PEPTIDE FRAGMENTS; STIFLE; TIBIA;

EID: 84883697009     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2013.774046     Document Type: Article

References (60)

1. Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P, et al. Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage 2008;16:638-46.
2. Lee JH, Dyke JP, Ballon D, Ciombor DM, Rosenwasser MP, Aaron RK. Subchondral fluid dynamics in a model of osteoarthritis: use of dynamic contrast-enhanced magnetic resonance imaging. Osteoarthritis Cartilage 2009;17:1350-5.
3. de Bri E, Reinholt FP, Svensson O. Primary osteoarthrosis in guinea pigs: a stereological study. J Orthop Res 1995;13:769-76.
4. Carlson CS, Loeser RF, Purser CB, Gardin JF, Jerome CP. Osteoarthritis in cynomolgus macaques. III: Effects of age, gender, and subchondral bone thickness on the severity of disease. J Bone Miner Res 1996;11:1209-17.
5. Naitou K, Kushida K, Takahashi M, Ohishi T, Inoue T. Bone mineral density and bone turnover in patients with knee osteoarthritis compared with generalized osteoarthritis. Calcif Tissue Int 2000; 66:325-9.
6. Hordon LD, Wright V, Smith MA. Bone mass in osteoarthritis. Ann Rheum Dis 1992;51:823-5.
7. Peel NFA, Barrington NA, Blumsohn A, Colwell A, Hannon R, Eastell R. Bone mineral density and bone turnover in spinal osteoarthrosis. Ann Rheum Dis 1995;54:867-71.
8. Li B, Aspden RM. Composition and mechanical properties of cancellous bone from the femoral head of patients with osteoporosis or osteoarthritis. J Bone Miner Res 1997;12:641-51.
9. Foss MVL, Byers PD. Bone density, osteoarthrosis of the hip, and fracture of the upper end of the femur. Ann Rheum Dis 1972;31: 259-64.
10. Haq I, Murphy E, Dacre J. Osteoarthritis. Postgrad Med J 2003;79:377-83.
11. Hunter DJ, March L, Sambrook PN. Knee osteoarthritis: the influence of environmental factors. Clin Exp Rheumatol 2002; 20:93-100.
12. Abernethy PJ, Townsend PR, Rose RM, Radin EL. Is chondromalacia patellae a separate clinical entity? J Bone Joint Surg Br 1978;60-B:205-10.
13. Burr DB, Schaffler MB. The involvement of subchondral mineralized tissues in osteoarthrosis: quantitative microscopic evidence. Microsc Res Tech 1997;37:343-57.
14. Radin EL, Paul IL, Rose RM. Role of mechanical factors in pathogenesis of primary osteoarthritis. Lancet 1972;299:519-22.
15. Radin EL, Abernethy PJ, Townsend PM, Rose RM. The role of bone changes in the degeneration of articular cartilage in osteoarthrosis. Acta Orthop Belg 1978;44:55-63.
16. Radin EL, Rose RM. Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop Relat Res 1986;34-40.
17. Felson DT, Neogi T. Osteoarthritis: is it a disease of cartilage or of bone? Arthritis Rheum 2004;50:341-4.
18. Fleisch H, Russell RGG, Bisaz S, Casey PA, Mühlbauer RC. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif Tissue Res 1968;Suppl:10-10a.
19. Fleisch H, Russell RGG, Simpson B, Mühlbauer RC. Prevention by a diphosphonate of immobilization 'osteoporosis' in rats. Nature 1969;223:211-12.
20. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-4.
21. Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005;7: R625-33.
22. Spector TD. Bisphosphonates: potential therapeutic agents for disease modification in osteoarthritis. Aging Clin Exp Res 2003; 15:413-18.
23. Bingham CO 3rd, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54:3494-507.
24. Garnero P, Aronstein WS, Cohen SB, Conaghan PG, Cline GA, Christiansen C, et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis Cartilage 2008;16:660-6.
25. Buckland-Wright JC, Messent EA, Bingham CO 3rd, Ward RJ, Tonkin C. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford) 2007;46:257-64.
26. Iwamoto J, Takeda T, Sato Y, Matsumoto H. Effects of risedronate on osteoarthritis of the knee. Yonsei Med J 2010;51:164-70.
27. Reid IR. Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. Skeletal Radiol 2011;40:1191-6.
28. Parfitt AM. The mechanism of coupling: a role for the vasculature. Bone 2000;26:319-23.
29. Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005;11:76-81.
30. Andersen TL, Sondergaard TE, Skorzynska KE, Dagnaes-Hansen F, Plesner TL, Hauge EM, et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol 2009;174:239-47.
31. Henriksen K, Flores C, Thomsen JS, Brüel AM, Thudium CS, Neutzsky-Wulff AV, et al. Dissociation of bone resorption and bone formation in adult mice with a non-functional V-ATPase in osteoclasts leads to increased bone strength. PLoS One 2011;6:e27482.
32. Fuchs RK, Phipps RJ, Burr DB. Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res 2008;23: 1689-97.
33. Recker RR, Armas L. The effect of antiresorptives on bone quality. Clin Orthop Relat Res 2011;469:2207-14.
34. Thomsen JS, Straarup TS, Danielsen CC, Oxlund H, Brüel A. Relationship between articular cartilage damage and subchondral bone properties and meniscal ossification in the Dunkin Hartley guinea pigmodel of osteoarthritis. Scand J Rheumatol 2011; 40:391-9.
35. Bendele AM, Hulman JF. Spontaneous cartilage degeneration in guinea pigs. Arthritis Rheum 1988;31:561-5.
36. Bendele AM. Animal models of osteoarthritis. J Musculoskelet Neuronal Interact 2001;1:363-76.
37. Tessier JJ, Bowyer J, Brownrigg NJ, Peers IS, Westwood FR, Waterton JC, et al. Characterisation of the guinea pig model of osteoarthritis by in vivo three-dimensional magnetic resonance imaging. Osteoarthritis Cartilage 2003;11:845-53.
38. Bendele AM. Animal models of osteoarthritis in an era of molecular biology. J Musculoskelet Neuronal Interact 2002;2:501-3.
39. Anderson-Mac Kenzie JM, Quasnichka HL, Starr RL, Lewis EJ, Billingham ME, Bailey AJ. Fundamental subchondral bone changes in spontaneous knee osteoarthritis. Int J Biochem Cell Biol 2005;37:224-36.
40. Huebner JL, Otterness IG, Freund EM, Caterson B, Kraus VB. Collagenase 1 and collagenase 3 expression in a guinea pig model of osteoarthritis. Arthritis Rheum 1998;41:877-90.
41. Wei L, Hjerpe A, Brismar BH, Svensson O. Effect of load on articular cartilage matrix and the development of guinea-pig osteoarthritis. Osteoarthritis Cartilage 2001;9:447-53.
42. Meyer JM, Farmer RW, Prenger MC. Risedronate but not alendronate slows disease progression in the guinea pig model of primary osteoarthritis. J Bone Miner Res 2001;16:S305.
43. Institute of Laboratory Animal Resources CoLSNRC guide for the care and use of laboratory animals. Washington, DC. USA. National Academy Press, 1996.
44. Pritzker KPH, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 2006;14:13-29.
45. Revell PA. Histomorphometry of bone. J Clin Pathol 1983; 36:1323-31.
46. Thomsen JS, Ebbesen EN, Mosekilde Li. A new method of comprehensive static histomorphometry applied on human lumbar vertebral cancellous bone. Bone 2000;27:129-38.
47. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999;96:133-8.
48. Barou O, Lafage-Proust MH, Martel C, Thomas T, Tirode F, Laroche N, et al. Bisphosphonate effects in rat unloaded hindlimb bone loss model: three-dimensional microcomputed tomographic, histomorphometric, and densitometric analyses. J Pharmacol Exp Ther 1999;291:321-8.
49. Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr Mol Med 2002;2:571-7.
50. Sugiyama T, Meakin LB, Galea GL, Jackson BF, Lanyon LE, Ebetino FH, et al. Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice. Bone 2011;49:133-9.#####
51. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 1998;38:375-88.
52. Thomsen JS, Mosekilde Li, Boyce RW, Mosekilde E. Stochastic simulation of vertebral trabecular bone remodeling. Bone 1994;15:655-66.
53. Shirai T, Kobayashi M, Nishitani K, Satake T, Kuroki H, Nakagawa Y, et al. Chondroprotective effect of alendronate in a rabbit model of osteoarthritis. J Orthop Res 2011;29:1572-7.
54. Jones MD, Tran CW, Li G, Maksymowych WP, Zernicke RF, Doschak MR. In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat. Arthritis Rheum 2010;62:2726-35.
55. Moreau M, Rialland P, Pelletier JP, Martel-Pelletier J, Lajeunesse D, Boileau C, et al. Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther 2011;13:R98.
56. Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004;50:1193-206.
57. Strassle BW, Mark L, Leventhal L, Piesla MJ, Jian L, X, Kennedy JD, et al. Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease. Osteoarthritis Cartilage 2010;18:1319-28.
58. Ding M, Danielsen CC, Hvid I. The effects of bone remodeling inhibition by alendronate on three-dimensional microarchitecture of subchondral bone tissues in guinea pig primary osteoarthrosis. Calcif Tissue Int 2008;82:77-86.
59. Allen MR, Turek JJ, Phipps RJ, Burr DB. Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate. Bone 2011;49: 128-32.
60. Bay-Jensen AC, Tabassi NC, Sondergaard LV, Andersen TL, Dagnaes-Hansen F, Garnero P, et al. The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover. Arthritis Res Ther 2009;11:R9.